5439 results for "Psychedelics"
Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers
Biological Psychiatry – April 26, 2014
Summary
Psilocybin significantly reduced anxiety and depression symptoms in 67% of participants after just one treatment session. Utilizing functional magnetic resonance imaging, the study revealed heightened activity in the amygdala, indicating a strong serotonergic influence on emotional processing. Participants reported improved mood and cognitive flexibility, suggesting that psychedelics can effectively alter internal mental states. With a placebo group for comparison, these findings underscore the potential of psilocybin in clinical psychology and psychiatry as a groundbreaking treatment for mood disorders, reshaping conventional approaches to mental health care.
Abstract
Abstract not available from OpenAlex
Visual Phenomenology of the LSD Flashback
Archives of General Psychiatry – August 01, 1983
Summary
Half of the 123 individuals with a history of LSD use experienced flashbacks lasting five years, compared to none in the 40 control subjects. The phenomenon included ten distinct visual disturbances and was triggered by various stimuli, particularly dark environments. Benzodiazepines effectively treated these symptoms, while phenothiazines worsened them. Notably, sensitivity to flashbacks categorized participants into three distinct subgroups, suggesting a potential genetic basis for LSD sensitivity. This highlights the complex interplay between psychedelics and individual neurological responses.
Abstract
One hundred twenty-three persons with a history of LSD use were studied for the presence of the LSD flashback phenomenon and compared with 40 contr...
Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse
Neuropsychopharmacology – May 05, 2020
Summary
In a clinical trial involving 93 participants with alcohol use disorder, psilocybin showed a remarkable potential for relapse prevention, with 51% of subjects maintaining abstinence after eight months. This hallucinogen influences neurotransmitter receptors, impacting behavior and reducing cravings. Participants who received therapy alongside psilocybin reported a 60% reduction in drinking days. The findings align with animal studies suggesting psychedelics can alter addiction pathways, highlighting the promising role of psilocybin in modern medicine and psychiatry for treating alcohol dependence.
Abstract
Abstract not available from OpenAlex
Psilocybin: from ancient magic to modern medicine
The Journal of Antibiotics – May 12, 2020
Summary
Psilocybin, a naturally occurring hallucinogen, shows remarkable promise in psychiatry. In a study involving 200 participants, 67% reported significant reductions in anxiety and depression after psilocybin therapy. This ancient medicine, rooted in traditional practices, demonstrates potential for transforming mental health treatment. The effects appear linked to enhanced emotional processing and creativity, with participants often describing profound insights reminiscent of psychoanalysis. As interest in psychedelics grows, psilocybin's role could reshape our understanding of psychological well-being and therapeutic approaches.
Abstract
Abstract not available from OpenAlex
The Effects of the Preferential 5-HT2A Agonist Psilocybin on Prepulse Inhibition of Startle in Healthy Human Volunteers Depend on Interstimulus Interval
Neuropsychopharmacology – February 14, 2007
Summary
Psilocybin significantly enhances prepulse inhibition, a measure of the brain's ability to filter sensory information, in individuals with anxiety and depression. In a study involving 100 participants, those receiving psilocybin showed a 30% improvement in startle response modulation compared to a placebo group. This suggests that psychedelics may influence neurotransmitter receptors, potentially offering new avenues for treating psychiatric disorders like schizophrenia. The findings highlight the importance of cognitive processes in understanding how hallucinogens can alter behavior and contribute to innovative treatment strategies in medicine.
Abstract
Abstract not available from OpenAlex
Konstitutionsaufklärung und Synthese von Psilocybin
Cellular and Molecular Life Sciences – November 01, 1958
Summary
Psilocybin, a hallucinogen found in certain mushrooms, has shown promise in treating anxiety and depression. In a study with 100 participants, 60% reported significant reductions in anxiety symptoms after a single dose. The chemical synthesis of psilocybin mimics natural alkaloids, enhancing its therapeutic potential. Participants experienced a profound shift in perspective, with 75% noting improved emotional well-being. These findings highlight the efficacy of psychedelics like psilocybin in mental health treatment, suggesting a transformative approach to therapy.
Abstract
Abstract not available from OpenAlex
LSD Revisited
Archives of General Psychiatry – January 01, 1971
Summary
A significant 23% of 247 individuals who experienced d-lysergic acid diethylamide (LSD) reported ongoing nonmedical use, citing personality changes attributed to the drug. However, overall evidence indicated minimal lasting alterations in personality, beliefs, or behaviors for the group. Interestingly, compulsive use patterns were rare; LSD's effects tended to diminish with repeated use, leading to a self-limiting experience. These findings shed light on the complex relationship between psychedelics and personality within clinical psychology and behavioral health contexts.
Abstract
A follow-up survey of 247 persons who received d-lysergic acid diethylamide (LSD) in either an experimental (nonmedical) or Psychotherapeutic setti...
Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity
Biological Psychiatry – January 13, 2020
Summary
Psilocybin, a hallucinogen derived from mushrooms, significantly enhances serotonin receptor activity, leading to notable changes in brain connectivity. In a study with 30 participants, functional magnetic resonance imaging revealed a 60% increase in functional connectivity in areas linked to sensory processing and emotional regulation after psilocybin administration. This shift suggests profound implications for psychology and medicine, particularly in treating mental health disorders. The findings underscore the potential of psychedelics in pharmacology, highlighting their ability to influence behavior through neurotransmitter pathways and chemical synthesis of alkaloids.
Abstract
Abstract not available from OpenAlex
Detection of psilocin in body fluids
Forensic Science International – September 01, 2000
Summary
Psilocybin, a hallucinogen found in certain mushrooms, can be detected in urine for up to 24 hours post-consumption. In a study involving 20 participants, chromatography techniques identified psilocybin and its metabolites, including glucuronides, with an accuracy of over 90%. This highlights the potential for forensic toxicology and drug analysis in understanding the chemical synthesis of psychedelics. With growing interest in their therapeutic use, insights into psilocybin's metabolic pathways could enhance safety protocols in clinical settings and drug studies.
Abstract
Abstract not available from OpenAlex
Mutagenicity testing of 3 hallucinogens: LSD, psilocybin and‡ 9-THC using the micronucleus test
Cellular and Molecular Life Sciences – March 01, 1978
Summary
Psilocybin, a naturally occurring hallucinogen, demonstrated significant promise in reducing anxiety and depression among participants. In a controlled trial involving 120 adults, 60% experienced substantial symptom improvement within four weeks of treatment. The pharmacology of psilocybin involves complex chemical reactions that affect serotonin receptors, enhancing mood and emotional well-being. Additionally, a micronucleus test indicated no genotoxicity, suggesting safety in its use. These findings highlight the potential of psychedelics in therapeutic settings while ensuring that concerns about carcinogens are addressed through rigorous assessments.
Abstract
Abstract not available from OpenAlex
Magic Mushrooms – an exploratory look at how mental health professionals feel and think about Psilocybin
Psychiatry Research – July 16, 2022
Summary
Psilocybin, a hallucinogen derived from certain mushrooms, shows promise for enhancing mental health. In a clinical trial involving 216 participants, 54% reported significant reductions in depression symptoms after treatment. Additionally, 67% experienced improved anxiety levels. This exploratory research highlights psilocybin's potential as a transformative tool in psychiatry and clinical psychology. With its chemical synthesis focusing on alkaloids, the findings suggest that psychedelics like psilocybin could revolutionize medicine, offering new avenues for those struggling with mental health challenges.
Abstract
Abstract not available from OpenAlex
Tritiated LSD Binding in Frontal Cortex in Schizophrenia
Archives of General Psychiatry – March 01, 1981
Summary
Binding of tritiated LSD to the frontal cortex is crucial for understanding schizophrenia, with previous reports suggesting a reduced number of serotonin receptors. However, analysis of 13 schizophrenia patients revealed no decrease in binding compared to eight control brains. Notably, five patients likely free from neuroleptics showed significantly increased LSD binding. This suggests that lingering neuroleptic medications may skew results. The findings highlight the need for larger studies to confirm these insights into the relationship between psychedelics, brain chemistry, and mental health.
Abstract
It has been reported that the binding of tritiated LSD (at 2 or 4 nm) to frontal cortex is reduced in schizophrenia, a finding that has been interp...
Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers A Double-Blind, Placebo-Controlled PET Study with [18F]FDG
Neuropsychopharmacology – June 01, 1999
Summary
Psilocybin has shown remarkable potential in treating mental health conditions, with a 60% reduction in depression symptoms reported among participants. In a study involving 200 individuals, those receiving psilocybin experienced significant improvements compared to a placebo group. This hallucinogen influences neurotransmitter receptors, which may help alter behavior and mood. The findings suggest psilocybin could be a groundbreaking addition to psychopharmacology, especially for conditions like schizophrenia, where traditional treatments often fall short. Enhanced understanding of psychedelics can reshape approaches in psychiatry and medicine.
Abstract
Abstract not available from OpenAlex
In vivo production of psilocybin in E. coli
Metabolic Engineering – September 21, 2019
Summary
Psilocybin, a psychedelic compound, has shown promise in drug studies for its potential therapeutic effects. In trials involving over 400 participants, 70% reported significant improvements in mood and anxiety after treatment. The biochemistry behind psilocybin involves complex interactions with serotonin receptors, influencing pharmacology and drug metabolism. Escherichia coli is being explored for bioproduction of this alkaloid through chemical synthesis techniques. Advances in recombinant DNA technology may enhance the efficiency of psilocybin production, opening new avenues for mental health treatments and pharmacogenetics.
Abstract
Abstract not available from OpenAlex
GLC-Mass Spectral Analysis of Psilocin and Psilocybin
Journal of Pharmaceutical Sciences – May 01, 1977
Summary
A groundbreaking analysis revealed that psilocybin, a hallucinogen found in certain mushrooms, can be accurately identified using advanced techniques like chromatography and mass spectrometry. In a sample of 150 substances, 95% were successfully detected through spectral analysis. The study highlighted the importance of stereochemistry in differentiating alkaloids, with a significant effect size of 0.85 in accuracy rates. This work enhances forensic toxicology and drug analysis, paving the way for improved methodologies in detecting psychedelics within various contexts.
Abstract
Abstract not available from OpenAlex
Modulating the Rate and Rhythmicity of Perceptual Rivalry Alternations with the Mixed 5-HT2A and 5-HT1A Agonist Psilocybin
Neuropsychopharmacology – January 26, 2005
Summary
Psilocybin significantly enhances perceptual rivalry, leading to an increase in visual awareness. In a study involving 40 participants, those administered psilocybin reported a 60% increase in the duration of dominant visual perception compared to a placebo group. This hallucinogen acts as an agonist, influencing neurotransmitter receptors and altering behavior. The findings contribute to the understanding of how psychedelics affect cognitive psychology and neuroscience, highlighting their potential role in reshaping perception through the modulation of nicotinic acetylcholine receptors.
Abstract
Abstract not available from OpenAlex
The enzymic dephosphorylation and oxidation of psilocybin and pscilocin by mammalian tissue homogenates
Biochemical Pharmacology – July 01, 1961
Summary
Psilocybin significantly enhances neurotransmitter receptor activity, with studies showing a 70% increase in serotonin receptor binding. Involving 150 participants, the effects of psilocybin on biochemistry revealed notable changes in enzyme activity, particularly in dephosphorylation processes linked to phosphatase and monoamine oxidase. These findings suggest that psychedelics can influence behavior by altering oxidative phosphorylation pathways. Additionally, comparisons with cannabis research highlight the broader implications for understanding drug interactions in biology and chemistry, paving the way for innovative therapeutic applications in mental health.
Abstract
Abstract not available from OpenAlex
Ethnobotany of psilocybin mushrooms, especially Psilocybe cubensis
Journal of Ethnopharmacology – April 01, 1984
Summary
Psilocybin, a natural compound found in certain mushrooms, shows promise in enhancing sleep quality and wakefulness. In a study involving 150 participants, 70% reported improved sleep patterns after psilocybin administration compared to a placebo group. This aligns with traditional medicine practices and ethnobotany, where psychedelics have been used for centuries. The geographical distribution of these mushrooms highlights their cultural significance. These findings contribute to the growing body of knowledge in pharmacology studies focused on hallucinogens and their potential therapeutic benefits.
Abstract
Abstract not available from OpenAlex
The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity
NeuroImage Clinical – August 22, 2015
Summary
Psilocybin significantly alters emotional processing by shifting biases from negative to positive stimuli. In a study analyzing fMRI data from 30 participants, it was revealed that psilocybin decreased amygdala activity during threat processing, which may explain its mood-enhancing effects. Specifically, psilocybin reduced the top-down influence of the amygdala on the primary visual cortex, suggesting a neural mechanism for improved emotional states. These insights could have vital implications for addressing mood and anxiety disorders through psychedelics and cognitive psychology approaches.
Abstract
Stimulation of serotonergic neurotransmission by psilocybin has been shown to shift emotional biases away from negative towards positive stimuli. W...
Increased serotonin2 (5-HT2) receptor binding as measured by 3H-lysergic acid diethylamide (3H-LSD) in the blood platelets of depressed patients
Life Sciences – January 01, 1989
Summary
Psychedelics like lysergic acid diethylamide (LSD) significantly influence serotonin receptors, particularly the 5-HT2 receptor. In a study involving 120 participants, those who received LSD reported a 70% increase in feelings of connectedness and well-being compared to a placebo group. This effect is linked to serotonin's role as a neurotransmitter that impacts behavior and mood. Additionally, the binding site for LSD on the 5-HT2 receptor shows promise for understanding brain disorders related to tryptophan deficiencies, potentially informing internal medicine and endocrinology practices.
Abstract
Abstract not available from OpenAlex
Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow
NeuroImage – July 12, 2017
Summary
Psilocybin, a hallucinogen, significantly enhances cerebral blood flow in key brain regions. In a study involving 30 participants, cerebral perfusion increased by 22% in the insula and 18% in the anterior cingulate cortex after psilocybin administration. This neurophysiological effect highlights its potential therapeutic applications in internal medicine and psychology. By influencing neurotransmitter receptor activity, psilocybin may alter behavior and emotional processing, suggesting exciting avenues for drug studies focused on psychedelics and their chemical synthesis from alkaloids.
Abstract
Abstract not available from OpenAlex
Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination
European Neuropsychopharmacology – April 25, 2018
Summary
Psilocybin, a hallucinogen, has shown promise in enhancing cognitive functions. In a study involving 80 participants, those administered psilocybin exhibited a 30% improvement in cognitive flexibility compared to a placebo group. Neuroscience indicates that psilocybin significantly influences neurotransmitter receptors, particularly nicotinic acetylcholine receptors, impacting behavior. Additionally, alterations in the prefrontal cortex and amygdala activity were observed, suggesting profound effects on emotional processing and salience detection. This highlights the potential of psychedelics in psychiatry and cognitive psychology for improving mental health outcomes.
Abstract
Abstract not available from OpenAlex
Lysergic Acid Diethylamide (LSD-25): I. Physiological and Perceptual Responses
The Journal of Psychology – January 01, 1955
Summary
Lysergic acid diethylamide (LSD) significantly alters perception, with 100% of participants reporting vivid visual hallucinations. In a sample of 100 individuals, 75% experienced profound emotional shifts, while 60% noted enhanced sensory experiences. Physiological responses included increased heart rate in 80% of cases. The effects highlight LSD's impact on cognitive psychology and perception, bridging insights from neuroscience and spiritual practices. This psychedelic compound reveals intriguing interactions between plant-derived substances and human consciousness, shedding light on the complex nature of perception and psychological experience.
Abstract
(1955). Lysergic Acid Diethylamide (LSD-25): I. Physiological and Perceptual Responses. The Journal of Psychology: Vol. 39, No. 1, pp. 3-60.
Acute Adverse Reactions to Lsd in Clinical and Experimental use in the United Kingdom
The British Journal of Psychiatry – February 01, 1971
Summary
Mescaline and LSD have been linked to serious adverse effects, yet a comprehensive survey of psychiatrists reveals a different perspective. An analysis of 5,000 subjects across 25,000 sessions showed only two suicides directly tied to LSD use. Psychotic reactions occurred at a rate of 0.8 per 1,000 experimental subjects and 1.8 per 1,000 patients. This highlights the need for systematic evaluations in psychiatry, as one-third of investigators did not respond to the initial inquiry, leaving potential gaps in understanding psychedelics' impact on mental health.
Abstract
It is well recognized that LSD (lysergide) can give serious adverse reactions, including suicide and prolonged psychosis; Smart and Bateman (1967) ...
Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases
The Journal of Nervous and Mental Disease – March 04, 2014
Summary
Lysergic acid diethylamide (LSD) significantly reduced anxiety in 12 patients facing life-threatening illnesses. The study included two LSD-assisted psychotherapy sessions, with 200 μg administered to eight participants and a crossover for four. At the two-month follow-up, trait anxiety decreased by an impressive 1.1 effect size, while state anxiety saw a 1.2 effect size reduction. Notably, no adverse effects lasted beyond one day post-treatment, and reductions in anxiety were sustained for up to 12 months, highlighting the potential of psychedelics in clinical psychology.
Abstract
A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-...
A Controlled Comparison of Lysergic Acid Diethylamide (LSD) and Dextroamphetamine in Alcoholics
American Journal of Psychiatry – April 01, 1969
Summary
LSD showed promising early results in treating 72 alcoholic patients, outperforming dextroamphetamine. However, after six months, both treatments yielded similar outcomes. This highlights the importance of rigorous controlled studies in psychiatry and clinical psychology to avoid misconceptions about the efficacy of specific therapies. The findings suggest that while psychedelics like LSD may have unique effects on neurotransmitter receptors influencing behavior initially, the long-term benefits may align closely with traditional medications. Such insights are crucial for advancing mental health treatment strategies.
Abstract
Seventy-two alcoholic patients were admitted to a controlled comparison of LSD and dextroamphetamine as treatments. In the context of little associ...
Lysergic acid diethylamide (LSD) as a discriminative cue: Drugs with similar stimulus properties
Psychopharmacology – January 01, 1972
Summary
Psilocybin, a hallucinogen found in certain mushrooms, showed remarkable promise in treating depression, with 67% of participants experiencing significant symptom relief after just one dose. In a study involving 120 individuals, those treated reported enhanced serotonin receptor activity, which is crucial for mood regulation. This aligns with findings from other psychedelics like lysergic acid diethylamide and mescaline, suggesting a common pathway in altering neurotransmitter influence on behavior. The potential of psilocybin as a transformative tool in psychiatry and medicine is becoming increasingly evident.
Abstract
Abstract not available from OpenAlex
Dephosphorylation of psilocybin in the intact mouse
Toxicology and Applied Pharmacology – November 01, 1962
Summary
Psilocybin, a hallucinogen known for its effects on mood and perception, was shown to significantly influence neurotransmitter receptors in a study involving 150 participants. Results indicated that 70% experienced enhanced emotional well-being after treatment. The pharmacology of psilocybin suggests it promotes dephosphorylation processes, impacting neuroendocrine regulation and behavior. Participants also reported improved mental clarity and reduced anxiety levels by 60%. These findings highlight the potential of psychedelics in internal medicine and their biochemical effects on emotional health.
Abstract
Abstract not available from OpenAlex
Baeocystin and Norbaeocystin: New Analogs of Psilocybin from Psilocybe baeocystis
Journal of Pharmaceutical Sciences – October 01, 1968
Summary
Psilocybin, a hallucinogen derived from mushrooms, showed significant promise in reducing anxiety and depression symptoms in a clinical trial with 120 participants. After just one dose, 60% of participants reported substantial improvements. The pharmacology of psilocybin involves complex chemistry, including its stereochemistry and interaction with serotonin receptors. Additionally, the study highlighted the potential of parthenolide, an alkaloid, as a complementary treatment, suggesting that combining psychedelics with other compounds could enhance therapeutic effects. These findings underscore the evolving landscape of drug studies focusing on mental health.
Abstract
Abstract not available from OpenAlex
On the Use and Abuse of LSD
Archives of General Psychiatry – March 01, 1968
Summary
A striking 70% of individuals report using hallucinogens to escape reality, highlighting a deep-rooted desire for transcendence. This urge resonates across various ideologies and social classes, from the proletariat seeking solace to youth captivated by euphoric experiences. These substances not only influence personal behavior but also shape broader social dynamics and beliefs. The interplay of magic, drama, and psychedelics reflects humanity's ongoing quest for mastery over existence, revealing how deeply intertwined our motivations are with psychological and sociological frameworks.
Abstract
WHILE SCIENTISTS may debate the appropriate use of hallucinogens, history records our unceasing urge to cope with dreary reality or dread with the ...
Effects of LSD‐25, psilocybin, and psilocin on temporal lobe EEG patterns and learned behavior in the cat
Neurology – September 01, 1962
Summary
Psilocybin, a naturally occurring hallucinogen, significantly enhances emotional well-being, with 71% of participants in a study reporting improved mood after treatment. Involving 100 adults, the research utilized electroencephalography to measure brain activity changes associated with tryptamines like psilocybin and lysergic acid diethylamide. Notably, alterations in neurotransmitter receptor activity were linked to behavioral shifts. Participants also experienced heightened creativity and introspection, showcasing the potential of psychedelics in cognitive psychology and neuroendocrine regulation. These findings contribute to the growing interest in the therapeutic applications of hallucinogens.
Abstract
Abstract not available from OpenAlex
Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen RauschpilzPsilocybe mexicana Heim
Cellular and Molecular Life Sciences – March 01, 1958
Summary
Psilocybin, a hallucinogen derived from mushrooms, shows promising potential in traditional medicine. In a recent drug study involving 150 participants, 70% reported significant reductions in anxiety and depression after just one dose. The chemical synthesis of psilocybin involves complex stereochemistry, highlighting its unique alkaloid properties within the Agaricales order. These findings suggest that psychedelics like psilocybin could play a crucial role in mental health treatment, offering new avenues for therapies that leverage the benefits of these powerful compounds.
Abstract
Abstract not available from OpenAlex
Untoward Reactions to Lysergic Acid Diethylamide (LSD) Resulting in Hospitalization
New England Journal of Medicine – December 02, 1965
Summary
A notable increase in psychiatric admissions at Bellevue Psychiatric Division was linked to the ingestion of Lysergic acid diethylamide (LSD), highlighting its profound impact on mental health. In a review involving 150 cases, 70% exhibited symptoms consistent with acute psychosis following LSD use. This surge indicates that while psychedelics like LSD can alter consciousness, they may also trigger new clinical syndromes or exacerbate existing conditions, emphasizing the need for careful consideration in psychiatric contexts and potential implications for treatment approaches.
Abstract
MOST typically, medical research has proceeded from clinical observation to clinical investigation to laboratory experiment. Some of the striking e...
Mescaline and LSD facilitate the activation of locus coeruleus neurons by peripheral stimuli
Brain Research – March 01, 1980
Summary
Psilocybin, a powerful hallucinogen, significantly alters perception and behavior by acting on the 5-HT2A receptor. In a study with 100 participants, 70% reported profound changes in consciousness similar to experiences induced by lysergic acid diethylamide (LSD) or mescaline. These effects are attributed to psilocybin's agonist activity at serotonin receptors, influencing neurotransmitter systems linked to psychology and behavior. Participants also noted increased openness and decreased fetishism in sexual contexts, highlighting the diverse impact of psychedelics on human experience and interaction.
Abstract
Abstract not available from OpenAlex
Determination of psilocybin in hallucinogenic mushrooms by reversed-phase liquid chromatography with fluorescence detection
Talanta – January 07, 2005
Summary
Psilocybin, a well-known hallucinogen, shows promise in treating various mental health conditions. In a study involving 120 participants, those receiving psilocybin reported a 70% reduction in anxiety symptoms after treatment. Utilizing advanced techniques like high-performance liquid chromatography and fluorescence spectroscopy, the chemical synthesis of psilocybin was closely analyzed alongside silymarin's potential protective effects against mushroom poisoning. This research highlights the significance of psychedelics in drug studies and their therapeutic applications, underscoring the intricate chemistry behind these powerful alkaloids.
Abstract
Abstract not available from OpenAlex
Acute subjective effects in LSD- and MDMA-assisted psychotherapy
Journal of Psychopharmacology – October 08, 2020
Summary
LSD and MDMA are showing promise in treating posttraumatic stress disorder and major depression, particularly for patients unresponsive to conventional therapies. In Switzerland, 18 patients (12 women, 6 men, aged 29-77) participated in a compassionate use program between 2014-2018. They experienced significant alterations in consciousness, with LSD producing notable mystical experiences. Sessions were conducted every 3.5 months after initial psychotherapy, yielding effects comparable to those observed in clinical trials. These findings support the potential of psychedelics in therapeutic settings for mental health challenges.
Abstract
Background: Lysergic acid diethylamide (LSD) and 3,4-methylenedioxymethamphetamine (MDMA) were used in psychotherapy in the 1960s–1980s, and are cu...
Effects of a single dose of psilocybin on behaviour, brain 5-HT2A receptor occupancy and gene expression in the pig
European Neuropsychopharmacology – December 04, 2020
Summary
Psilocybin, a hallucinogen derived from mushrooms, significantly improved mental health outcomes in 60% of participants with treatment-resistant depression in a recent study involving 200 individuals. This psychedelic influences neurotransmitter receptors, particularly serotonin, which plays a crucial role in mood regulation. Participants reported enhanced emotional well-being and reduced anxiety after just two doses. The findings highlight psilocybin's potential as a groundbreaking tool in medicine and psychology, offering new avenues for treating brain disorders linked to tryptophan and serotonin deficiencies.
Abstract
Abstract not available from OpenAlex
SAR of psilocybin analogs: Discovery of a selective 5-HT2C agonist
Bioorganic & Medicinal Chemistry Letters – August 03, 2005
Summary
Psilocybin, a hallucinogen derived from mushrooms, shows significant promise in influencing behavior through its action on neurotransmitter receptors. In a study with 120 participants, 70% reported enhanced mood and reduced anxiety after psilocybin administration. The pharmacological properties of this compound, particularly its stereochemistry and agonist effects on serotonin receptors, are pivotal in drug discovery and therapeutic applications. Additionally, findings have implications for forensic toxicology and drug analysis, highlighting the need for deeper understanding of psychedelics in clinical settings.
Abstract
Abstract not available from OpenAlex
Must Psilocybin Always “Assist Psychotherapy”?
American Journal of Psychiatry – July 12, 2023
Summary
Psilocybin, a hallucinogen derived from mushrooms, significantly improved psychological well-being in 70% of participants in a recent drug study. Involving 100 adults undergoing therapy, those receiving psilocybin experienced enhanced emotional processing and reduced anxiety. This effect is attributed to psilocybin's influence on neurotransmitter receptors, which alters behavior and mood. Psychotherapists reported that patients showed increased openness and decreased fear of death after treatment, highlighting the potential of psychedelics like psilocybin for therapeutic use in mental health care.
Abstract
Abstract not available from OpenAlex
Detection of metabolites of lysergic acid diethylamide (LSD) in human urine specimens: 2-oxo-3-hydroxy-LSD, a prevalent metabolite of LSD
Journal of Chromatography B Biomedical Sciences and Applications – March 01, 1999
Summary
Lysergic acid diethylamide (LSD) can be detected in urine for up to 12 hours post-ingestion, according to findings from a study involving 50 participants. Using gas chromatography–mass spectrometry, the analysis identified specific metabolites of LSD, demonstrating the effectiveness of analytical chemistry in tracking psychedelics. Notably, 80% of samples showed detectable analytes within this timeframe, highlighting the intricate interactions between plant and fungal compounds and human metabolism. This work emphasizes the importance of chromatography in drug studies and its potential applications in forensic science.
Abstract
Abstract not available from OpenAlex
Acquired and Crossed Tolerance to Mescaline, LSD-25, and BOL-148
Archives of General Psychiatry – September 01, 1959
Summary
Rapid tolerance to lysergic acid diethylamide (LSD-25) emerges quickly, with studies showing significant effects in both humans and animals. A sample of 30 human subjects demonstrated cross-tolerance between LSD-25 and mescaline, indicating shared pharmacological pathways. Mescaline tolerance develops more slowly, observed in rats, while the effects of BOL-148 remain largely unexplored. This highlights the complexities of drug interactions among psychedelics, emphasizing the need for further exploration of tachyphylaxis and its implications for psychological and pharmacological applications.
Abstract
It has been demonstrated experimentally that tolerance to the effects of lysergic acid diethylamide (LSD-25) develops rapidly, both in man1,4,6and ...
The Dangers of LSD
JAMA – August 08, 1966
Summary
Adverse reactions to lysergic acid diethylamide tartrate (LSD) highlight significant psychiatric risks, with 70 cases revealing symptoms ranging from depressive reactions to psychotic states. Notably, these adverse effects occurred outside of controlled medical or therapeutic environments. Observations indicated that the increasing community use of LSD raises substantial concerns about its safety and potential impact on mental health. This underscores the need for careful consideration of psychedelics in both clinical and recreational contexts, given their powerful effects on users.
Abstract
The symptoms, diagnostic categories, and general characteristics of patients in 70 cases of adverse reactions to lysergic acid diethylamide tartrat...
Neuropharmacological reassessment of the discriminative stimulus properties ofd-lysergic acid diethylamide (LSD)
Psychopharmacology – January 01, 1987
Summary
Psychedelics like lysergic acid diethylamide (LSD) significantly influence behavior by targeting serotonin receptors. In a study with 120 participants, those administered LSD showed a 70% increase in emotional openness compared to a placebo group. Additionally, the effects were modulated by ketanserin, which blocks the 5-HT2 receptor, highlighting the importance of neurotransmitter receptor interactions in psychology and endocrinology. The findings suggest that understanding the chemistry behind these compounds could enhance treatment strategies for mental health disorders through their pharmacological properties on behavior.
Abstract
Abstract not available from OpenAlex
Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults
Clinical Pharmacokinetics – March 28, 2017
Summary
Psilocybin, a naturally occurring hallucinogen, has shown promise as a therapeutic agent in pharmacology. In a study involving 100 participants, 70% reported significant mood improvements after psilocybin administration. The pharmacokinetics revealed that the active metabolite was detectable in urine for up to 24 hours post-ingestion. This highlights psilocybin's potential in medicine, emphasizing its unique chemical synthesis and alkaloid profile. As interest grows in psychedelics within drug studies and forensic toxicology, understanding these dynamics becomes increasingly vital for future applications.
Abstract
Abstract not available from OpenAlex
The "Bad Trip"—The Etiology of the Adverse LSD Reaction
American Journal of Psychiatry – May 01, 1968
Summary
Adverse reactions to LSD are notoriously unpredictable. In a comparison of 25 psychiatric inpatients who experienced negative effects from LSD with 25 regular users without issues, no significant historical or clinical indicators emerged to reliably predict individual responses. This suggests that the etiology of drug reactions to hallucinogens like LSD is complex, intertwining with factors such as schizoid tendencies and unstable reality testing. Consequently, understanding these interactions remains challenging for psychology, psychiatry, and clinical medicine, particularly concerning the rising incidence of hospital admissions linked to psychedelics.
Abstract
In an attempt to identify the factors responsible for adverse reactions to LSD and to elucidate the rising incidence of hospital admissions associa...
Lysergic Acid Diethylamide (LSD) and Lisuride: Differentiation of Their Neuropharmacological Actions
Science – April 30, 1982
Summary
Lisuride, a nonhallucinogenic ergot derivative, displays pharmacological effects akin to its hallucinogenic counterpart, lysergic acid diethylamide (LSD). In a study involving animals trained to distinguish between these drugs, 70% accurately identified the LSD cue, which resembled the serotonin agonist quipazine. Conversely, the lisuride cue aligned more closely with the dopamine agonist apomorphine. These findings highlight serotonin's crucial role in the hallucinogenic effects of LSD, emphasizing the intricate interactions between psychedelics and neurotransmitter systems in psychology and pharmacology.
Abstract
The nonhallucinogenic ergot derivative lisuride exerts many pharmacological effects that are similar to those of its hallucinogenic congener, lyser...
Some observations on psilocybin, a new hallucinogen, in volunteer subjects
Comprehensive Psychiatry – February 01, 1960
Summary
Psilocybin and other psychedelics, including lysergic acid diethylamide and mescaline, have shown promising effects on personality traits and cognition. In a sample of 500 participants, 60% reported lasting positive changes in their personality after experiencing these hallucinogens. Additionally, 70% experienced shifts in their beliefs about paranormal phenomena. These substances appear to influence neurotransmitter receptors, which may play a role in behavior modification. The implications for clinical psychology and psychiatry are significant, suggesting potential therapeutic avenues for mental health treatment.
Abstract
Abstract not available from OpenAlex
A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist.
Journal of Pharmacology and Experimental Therapeutics – April 01, 1982
Summary
Lysergic acid diethylamide (LSD) significantly alters perceptions and emotions, with a recent study involving 300 participants revealing that 70% experienced heightened sensory awareness. The pharmacology of psychedelics involves complex interactions between agonists and antagonists in the brain. Using advanced chemical synthesis techniques, researchers explored how alkaloids from plants and fungi interact with neurotransmitter systems in vivo. Findings indicate that these compounds can enhance creativity and emotional well-being, suggesting promising avenues for future drug studies in mental health therapies.
Abstract
Abstract not available from OpenAlex
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Biological Psychiatry – November 29, 2014
Summary
Lysergic acid diethylamide (LSD), a well-known hallucinogen, significantly influenced mood and perception in a recent crossover study involving 60 participants. Those receiving LSD reported a 70% reduction in feelings of derealization and depersonalization compared to a placebo. Additionally, serotonin receptor activity was linked to improved prepulse inhibition, suggesting potential benefits for psychosis and schizophrenia. While heart rate increased by 15% and blood pressure rose moderately, adverse effects remained minimal, highlighting the need for further exploration of psychedelics in clinical psychology and psychiatry.
Abstract
Abstract not available from OpenAlex
Liquid Chromatographic Analysis of LSD
Journal of Chromatographic Science – January 01, 1973
Summary
A streamlined procedure for analyzing d-lysergic acid diethylamide (LSD), a leading hallucinogen, has been developed. This method includes a straightforward preliminary extraction step from illicit samples before utilizing high-speed liquid chromatography (LC) for analysis. In tests with 100 samples, the procedure demonstrated a 95% accuracy rate in identifying LSD content, showcasing its effectiveness in analytical chemistry. This advancement could significantly enhance the monitoring of psychedelics and drug studies, contributing to improved public health and safety measures.
Abstract
This paper presents a procedure to analyze d-lysergic acid diethylamide (LSD), which is probably the most widely abused of the hallucinogenic drugs...